Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD

Blood (2009) 114 (22): 636.

https://doi.org/10.1182/blood.V114.22.636.636

Published: 2009

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Nam H. Dang, MD, PhD, Mitchell R Smith, MD, PhD, Fritz Offner, MD, Gregor Verhoef, MD, Peter Johnson, MD, Ama Z S Rohatiner, MD, Jonathan L. Kaufman, MD, Eva Gine, M.D., Bertrand Coiffier, MD, Myron S Czuczman, MD, James Foran, MD, Simon Durrant, MD, Steven Hua, PhD, Erik R. Vandendries, MD, PhD, Luis Fayad, MD

Blood (2009) 114 (22): 584.

https://doi.org/10.1182/blood.V114.22.584.584

Published: 2009

Journal Articles

Outcome of Aurora Kinase Inhibition of Acute Myeloid Leukemia by AT9283 Is Dependent upon the Presence or Absence of Mutations in Type 1 Oncogenic Kinase Signalling Pathways.

John Goodall, Matthew S Squires, Vicky Lock, Farhad Ravandi, MBBS, Hagop M Kantarjian, James Foran, MD, Neil T Thompson, John F Lyons

Blood (2008) 112 (11): 1613.

https://doi.org/10.1182/blood.V112.11.1613.1613

Published: 2008

Journal Articles

Phase I Study of Clofarabine with Standard-Dose Infusional Cytarabine (Ara-C) as Intensive Induction Therapy for Newly-Diagnosed De Novo Acute Myeloid Leukemia in Older Adults Age ≥60 Years.

James Foran, MD, Angelina The, MD, Pam Dixon, RN, Marcel Devetten, MD, Mikkael Sekeres, MD

Blood (2007) 110 (11): 1831.

https://doi.org/10.1182/blood.V110.11.1831.1831

Published: 2007

Journal Articles

Phase II Study of R-CHOP Followed by 90 Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.

Mitchell R. Smith, MD, PhD, Lijun Zhang, Leo I. Gordon, MD, James Foran, MD, Brad Kahl, MD, Randy D. Gascoyne, MD, Ranjana Advani, MD, Elisabeth Paietta, MD, Edie Weller, PhD, Sandra J. Horning, MD

Blood (2007) 110 (11): 389.

https://doi.org/10.1182/blood.V110.11.389.389

Published: 2007

Journal Articles

A Phase I Trial of AT9283, a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies.

Farhad Ravandi, MD, James Foran, MD, Srdan Verstovsek, MD, PhD, Jorge Cortes, MD, William Wierda, MD, PhD, Patricia Boone, Gautam Borthakur, Trish Sweeney, PhD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 904.

https://doi.org/10.1182/blood.V110.11.904.904

Published: 2007

Journal Articles

A Comparative Study of Diffuse Large B-Cell Lymphoma (DLBCL) between African Americans and Caucasians: Single-Center Experience at the University of Alabama at Birmingham (UAB).

Angelina The, MD, Yufeng Li, PhD, Vishnu Reddy, MD, Randall Davis, MD, Melissa Baird, MD, James Foran, MD

Blood (2007) 110 (11): 4430.

https://doi.org/10.1182/blood.V110.11.4430.4430

Published: 2007

Journal Articles

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Luis Fayad, MD, Hemant Patel, PhD, Gregor Verhoef, MD, PhD, Myron Czuczman, MD, James Foran, MD, Eva Gine, MD, Ama Rohatiner, MD, Mitchell R. Smith, MD, Mark Shapiro, MD, PhD, Anjali Advani, MD

Blood (2006) 108 (11): 2711.

https://doi.org/10.1182/blood.V108.11.2711.2711

Published: 2006

NARROW

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Outcome of Aurora Kinase Inhibition of Acute Myeloid Leukemia by AT9283 Is Dependent upon the Presence or Absence of Mutations in Type 1 Oncogenic Kinase Signalling Pathways.

Phase I Study of Clofarabine with Standard-Dose Infusional Cytarabine (Ara-C) as Intensive Induction Therapy for Newly-Diagnosed De Novo Acute Myeloid Leukemia in Older Adults Age ≥60 Years.

Phase II Study of R-CHOP Followed by 90 Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.

A Phase I Trial of AT9283, a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies.

A Comparative Study of Diffuse Large B-Cell Lymphoma (DLBCL) between African Americans and Caucasians: Single-Center Experience at the University of Alabama at Birmingham (UAB).

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only